CN1243741C - 喹啉基和苯并噻唑基PPAR－γ调节剂 - Google Patents

喹啉基和苯并噻唑基PPAR－γ调节剂 Download PDF

Info

Publication number
CN1243741C
CN1243741C CNB018120172A CN01812017A CN1243741C CN 1243741 C CN1243741 C CN 1243741C CN B018120172 A CNB018120172 A CN B018120172A CN 01812017 A CN01812017 A CN 01812017A CN 1243741 C CN1243741 C CN 1243741C
Authority
CN
China
Prior art keywords
compound
chloro
nmr
dmso
dichloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018120172A
Other languages
English (en)
Chinese (zh)
Other versions
CN1438998A (zh
Inventor
L·R·姆克吉
J·B·乌泽
S·M·鲁本斯坦
新海久
古川昇
荻原笃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exmes Gen Sf Co ltd
Quest Discovery Ltd
Japan Tobacco Inc
Amgen Inc
Original Assignee
Japan Tobacco Inc
Tularik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Tularik Inc filed Critical Japan Tobacco Inc
Publication of CN1438998A publication Critical patent/CN1438998A/zh
Application granted granted Critical
Publication of CN1243741C publication Critical patent/CN1243741C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Quinoline Compounds (AREA)
  • Holo Graphy (AREA)
CNB018120172A 2000-06-28 2001-06-27 喹啉基和苯并噻唑基PPAR－γ调节剂 Expired - Lifetime CN1243741C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21481000P 2000-06-28 2000-06-28
US60/214,810 2000-06-28

Publications (2)

Publication Number Publication Date
CN1438998A CN1438998A (zh) 2003-08-27
CN1243741C true CN1243741C (zh) 2006-03-01

Family

ID=22800496

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018120172A Expired - Lifetime CN1243741C (zh) 2000-06-28 2001-06-27 喹啉基和苯并噻唑基PPAR－γ调节剂

Country Status (25)

Country Link
EP (1) EP1296967B1 (enExample)
JP (1) JP4515026B2 (enExample)
KR (1) KR100771286B1 (enExample)
CN (1) CN1243741C (enExample)
AT (1) ATE327984T1 (enExample)
AU (2) AU2001271637B2 (enExample)
BR (1) BRPI0112115B8 (enExample)
CA (1) CA2412723C (enExample)
CY (1) CY1105126T1 (enExample)
CZ (1) CZ302982B6 (enExample)
DE (1) DE60120163T2 (enExample)
DK (1) DK1296967T3 (enExample)
EA (1) EA005976B1 (enExample)
ES (1) ES2265435T3 (enExample)
HK (1) HK1052351B (enExample)
HU (1) HUP0301482A3 (enExample)
IL (2) IL153461A0 (enExample)
MX (1) MXPA02012708A (enExample)
NO (1) NO325448B1 (enExample)
NZ (1) NZ523229A (enExample)
PL (1) PL214670B1 (enExample)
PT (1) PT1296967E (enExample)
SK (1) SK288236B6 (enExample)
WO (1) WO2002000633A1 (enExample)
ZA (1) ZA200210283B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
ES2530235T3 (es) 2003-02-13 2015-02-27 Wellstat Therapeutics Corporation Compuestos para el tratamiento de trastornos metabólicos
EP1613298A4 (en) * 2003-04-11 2007-10-03 Univ Tennessee Res Foundation Lysophosphatidic Acid Analysis and Inhibition of Neointimal Formation
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
DE602005020313D1 (de) 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
US7820721B2 (en) 2006-01-25 2010-10-26 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
EP1976510A4 (en) 2006-01-25 2010-06-09 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
JP2009525982A (ja) 2006-02-02 2009-07-16 ウェルスタット セラピューティクス コーポレイション 代謝障害の治療のための化合物
JP5291471B2 (ja) * 2006-02-15 2013-09-18 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
US8030324B2 (en) * 2006-09-21 2011-10-04 Piramal Life Sciences Ltd. Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia
WO2012162463A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物，其药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
AU759255B2 (en) * 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
WO2001000579A1 (en) * 1999-06-30 2001-01-04 Tularik Inc. COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY

Also Published As

Publication number Publication date
AU2001271637B2 (en) 2006-05-04
JP4515026B2 (ja) 2010-07-28
NO20026156D0 (no) 2002-12-20
HUP0301482A3 (en) 2005-12-28
CA2412723A1 (en) 2002-01-03
EA200300078A1 (ru) 2003-08-28
SK288236B6 (sk) 2015-01-07
BR0112115A (pt) 2003-04-29
CZ302982B6 (cs) 2012-02-01
DK1296967T3 (da) 2006-10-02
EP1296967A1 (en) 2003-04-02
EA005976B1 (ru) 2005-08-25
PL214670B1 (pl) 2013-08-30
KR100771286B1 (ko) 2007-10-29
NO325448B1 (no) 2008-05-05
CZ20024197A3 (cs) 2003-06-18
IL153461A0 (en) 2003-07-06
IL153461A (en) 2007-10-31
PT1296967E (pt) 2006-10-31
ES2265435T3 (es) 2007-02-16
SK18352002A3 (sk) 2003-04-01
CN1438998A (zh) 2003-08-27
AU7163701A (en) 2002-01-08
PL359996A1 (en) 2004-09-06
HK1052351B (en) 2006-11-03
MXPA02012708A (es) 2003-09-22
WO2002000633A1 (en) 2002-01-03
KR20030024713A (ko) 2003-03-26
ATE327984T1 (de) 2006-06-15
BRPI0112115B1 (pt) 2016-07-26
DE60120163D1 (de) 2006-07-06
CA2412723C (en) 2010-12-14
HUP0301482A2 (hu) 2003-09-29
DE60120163T2 (de) 2007-04-12
NZ523229A (en) 2004-10-29
CY1105126T1 (el) 2010-03-03
HK1052351A1 (en) 2003-09-11
JP2004501905A (ja) 2004-01-22
ZA200210283B (en) 2005-09-28
EP1296967B1 (en) 2006-05-31
BRPI0112115B8 (pt) 2021-05-25
NO20026156L (no) 2003-02-25

Similar Documents

Publication Publication Date Title
CN1171872C (zh) 调节PPARγ活性的化合物
CN1438998A (zh) 喹啉基和苯并噻唑基PPAR－γ调节剂
CN1184215C (zh) 作为HPPARα激活剂的、取代的噁唑与噻唑衍生物
CN1038413C (zh) 用于治疗的酰胺的制备方法
CN1585638A (zh) 被连接的联芳基化合物
CN1164579C (zh) 噻唑和噁唑衍生物以及它们的药物应用
CN1217936C (zh) 含有磺酰胺的杂环化合物
CN1085663C (zh) 作为解痛剂的芳族氨基醚
CN1151140C (zh) 葡糖激酶活化剂
CN1308297C (zh) 氨基磺酸苯基酯衍生物
CN1210263C (zh) N－羟基－2－(烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基)－3－取代的酰胺、其制备及用作抑制剂
CN1767823A (zh) 哮喘和过敏性炎症调节剂
CN1118457C (zh) 新的环状二胺化合物及含有它的药物
CN1909902A (zh) 用于治疗糖尿病的作为ppar调节剂的三唑、噁二唑和噻二唑衍生物
CN1791572A (zh) 新化合物
CN1738796A (zh) 二芳基磺酰胺化合物
CN1784387A (zh) 新的苯并咪唑衍生物
CN1638768A (zh) 调节ppar活性的噻唑和噁唑衍生物
CN1039809A (zh) 取代的氨甲基四氢化萘及其杂环同系物的制备
HK1045504A1 (en) ω-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
CN1671659A (zh) 新的取代吲哚
CN1703397A (zh) 磺酰基氨基－乙酸衍生物及其作为阿立新受体拮抗剂的应用
CN1812977A (zh) 取代羧酸
CN1529695A (zh) 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺、其制备方法、其用作药物或诊断剂的用途以及含有所述化合物的药物制剂
CN1675168A (zh) 丙酸衍生物及其作为hPPAR活化剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: AMGEN CO., LTD.; JAPAN TOBACCO INC.

Free format text: FORMER OWNER: AMGEN INC; JAPAN TOBACCO INC.

Effective date: 20061208

Owner name: LLANO EXPLORATION LTD.; JAPAN TOBACCO INC.

Free format text: FORMER OWNER: FIGURE LARIC CO., LTD.; JAPAN TOBACCO INC.

Effective date: 20061208

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: AMGEN INC; JAPAN TOBACCO INC.

Free format text: FORMER NAME OR ADDRESS: LLANO EXPLORATION LTD.; JAPAN TOBACCO INC.

CP01 Change in the name or title of a patent holder

Address after: Delaware

Co-patentee after: JAPAN TOBACCO Inc.

Patentee after: Exmes Gen SF Co.,Ltd.

Address before: Delaware

Co-patentee before: JAPAN TOBACCO Inc.

Patentee before: Quest discovery Ltd.

TR01 Transfer of patent right

Effective date of registration: 20061208

Address after: California, USA

Co-patentee after: JAPAN TOBACCO Inc.

Patentee after: AMGEN Inc.

Address before: Delaware

Co-patentee before: JAPAN TOBACCO Inc.

Patentee before: Exmes Gen SF Co.,Ltd.

Effective date of registration: 20061208

Address after: Delaware

Co-patentee after: JAPAN TOBACCO Inc.

Patentee after: Quest discovery Ltd.

Address before: California, USA

Co-patentee before: JAPAN TOBACCO Inc.

Patentee before: Tularik Inc.

CX01 Expiry of patent term

Granted publication date: 20060301

CX01 Expiry of patent term